Samsung Bioepis and Intuscell have signed a formal agreement for the joint development and commercialization of the antibody-drug conjugate (ADC) candidate 'SBE303.' The two companies will begin follow-up development of the first candidate since their joint research contract in 2023.
On July 22, Samsung Bioepis and Intuscell announced the signing of the formal contract for the first candidate in their ADC drug joint development project.
In December 2023, the two companies entered into a joint research agreement to discover up to five ADC drug candidates. This latest contract focuses on the follow-up research and commercialization of SBE303, a candidate targeting the Nectin-4 protein, which is currently undergoing global Phase 1 clinical trials. The candidate combines Samsung Bioepis' antibody with Intuscell's linker technology and Frontline's payload from China, developed through open innovation.
The contract includes development and sales milestones as well as royalty conditions based on revenue, but the total contract size and specific terms have not been disclosed by the companies.
Kim Kyung-ah, CEO of Samsung Bioepis, stated, "This contract marks an important milestone in expanding our business into the next generation of cancer treatments through collaboration with domestic companies. We will continue to pursue innovative research and development to address various unmet medical needs."
Meanwhile, Samsung Bioepis presented preclinical research results for SBE303 at the American Association for Cancer Research (AACR) annual meeting in April, confirming the potential for improved antibody-tumor cell binding specificity and intracellular drug delivery efficiency compared to existing Nectin-4 targeted cancer therapies.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.